VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety

References

• Nelson DL, Lehninger AL, Cox MM. Lehninger principles of biochemistry. New York (NY): W. H. Freeman; 2008.
   Google Scholar
• Patrick GL. An introduction to medicinal chemistry. UK: Oxford University Press; 2013.
   Google Scholar
• Radha V, Nambirajan S, Swarup G. Association of Lyn tyrosine kinase with the nuclear matrix and cell‐cycle‐dependent changes in matrix‐associated tyrosine kinase activity. Eur J Biochem 1996;236:352–9.
   PubMedGoogle Scholar
• Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–5.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298–307.
   PubMed Web of Science ®Google Scholar
• Pralhad T, Madhusudan S, Rajendrakumar K. Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol 2003;55:1045–53.
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359–71.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28–39.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327–37.
   PubMed Web of Science ®Google Scholar
• Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358–64.
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855–67.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102:7665–70.
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178–89.
   PubMed Web of Science ®Google Scholar
• Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: US Food and Drug Administration drug approval summary. Clin Cancer Res 2012;18:3722–30.
   PubMed Web of Science ®Google Scholar
• Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: autocrine signalling by VEGF. VEGF Cancer 2004;133–44.
   Google Scholar
• Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540–5.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–6.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Héry C, Autier P, et al. Global burden of breast cancer. In: Christopher Li, ed. Breast Cancer Epidemiology. Springer; 2010:1–19.
   Google Scholar
• Zakharia Y, Zakharia K, Rixe O. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma. Expert Opin Drug Discov 2015;10:925–35.
   PubMed Web of Science ®Google Scholar
• Fratto M, Imperatori M, Vincenzi B, et al. New perspectives: role of Sunitinib in breast cancer. Clin Ter 2010;162:251–7.
   Web of Science ®Google Scholar
• Ranieri G, Patruno R, Ruggieri E, et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006;13:1845–57.
   PubMed Web of Science ®Google Scholar
• Patel RR, Sengupta S, Kim HR, et al. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer 2010;46:1537–53.
   PubMed Web of Science ®Google Scholar
• Norman MH, Liu L, Lee M, et al. Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives. J Med Chem 2012;55:1858–67.
   PubMed Web of Science ®Google Scholar
• Kiselyov AS, Semenov VV, Milligan D. 4‐(Azolylphenyl)‐phthalazin‐1‐amines: novel inhibitors of VEGF receptors I and II. Chem Biol Drug Des 2006;68:308–13.
   PubMed Web of Science ®Google Scholar
• Papakyriakou A, Katsarou ME, Belimezi M, et al. Discovery of potent vascular endothelial growth factor receptor‐2 inhibitors. ChemMedChem 2010;5:118–29.
   PubMed Web of Science ®Google Scholar
• Harmey JH, Bouchier‐Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti‐angiogenic therapy. Bioessays 2002;24:280–3.
   PubMed Web of Science ®Google Scholar
• Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374–8.
   PubMed Web of Science ®Google Scholar
• Casini A, Scozzafava A, Mincione F, et al. Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects. J Med Chem 2000;43:4884–92.
   PubMed Web of Science ®Google Scholar
• Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X L sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 2001;8:705–11.
   PubMed Web of Science ®Google Scholar
• Kappe CO. A reexamination of the mechanism of the Biginelli dihydropyrimidine synthesis. Support for an N-Acyliminium ion intermediate(1). J Org Chem 1997;62:7201–4.
   PubMed Web of Science ®Google Scholar
• Martin SJ. Caspases: executioners of apoptosis. Pathobiol Human Dis 2014;145–52.
   Google Scholar
• Rudel T. Caspase inhibitors in prevention of apoptosis. Herz 1999;24:236–41.
   PubMed Web of Science ®Google Scholar
• Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37–43.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003;195:158–67.
   PubMed Web of Science ®Google Scholar
• Callagy GM, Webber MJ, Pharoah PD, et al. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008;8:153.
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t (14; 18). Nature 1991;349:254–6.
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhang J, Xue N, et al. Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells. Invest New Drugs 2010;28:493–501.
   PubMed Web of Science ®Google Scholar
• MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995;5:127–56.
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–12.
   PubMed Web of Science ®Google Scholar